Elsevier

Biochimie

Volume 165, October 2019, Pages 245-249
Biochimie

Short communication
Antithrombin is incorporated into exosomes produced by antithrombin non-expressing cells

https://doi.org/10.1016/j.biochi.2019.08.010Get rights and content

Highlights

  • Antithrombin is found in exosomes released by cells that do not express antithrombin.

  • A fraction of antithrombin binds covalently HTRA1 on the surface of exosomes.

  • Deprival of serum induces HTRA1 overexpression as a result of the UPR response.

Abstract

Antithrombin is a serine protease inhibitor that exerts a crucial role in hemostasis as the main inhibitor of the coagulation cascade. It plays also critical roles in other processes, such as inflammation and cancer. Here we show that exosomes released by Madin-Darby canine kidney (MDCK) cells cultured in the presence of heparin incorporate antithrombin from the serum. Exosomal antithrombin is found complexed with the serine protease high temperature requirement A1 (HTRA1), whose cellular levels are increased after serum deprival, the condition used to collect exosomes. Although the biological relevance of the presence of antithrombin in exosomes remains to be investigated, our results suggest a functional interplay between antithrombin and HTRA1.

Introduction

Extracellular vesicles carrying proteins, lipids, metabolites, RNA and DNA, are cell-secreted vesicles that are involved in intercellular communication [1]. They play crucial roles in inflammation and cancer and are regarded as ideal biomarkers for different diseases [2]. There are two main types of exovesicles: exosomes (30–150 nm) that originate in the endocytic pathway and are released after fusion of multivesicular bodies with the plasma membrane, and microvesicles (100–1000 nm) that form directly by plasma membrane budding [1,2].

Antithrombin is a plasma serpin that upon binding to heparin acts as the main inhibitor of the coagulation proteases [3]. In addition to its function in hemostasis, antithrombin has been found to exert anti-inflammatory, anti-angiogenic, anti-apoptotic, anti-viral and anti-tumor roles [4]. Proteomic studies have identified antithrombin as a component of exosomes from different cell types (www.exocarta.org). However, little is known about the origin and functional relevance of exosomal antithrombin.

In this work, we have identified serum antithrombin incorporated into exosomes from Madin-Darby canine kidney (MDCK) cells, which do not synthesize this protein. Exosomal antithrombin was found complexed with serine protease high temperature requirement A1 (HTRA1).

Section snippets

Cell culture, isolation of exosomes and western blotting

Cells were routinely cultured in Dulbecco's modified Eagle's medium (DMEM) as reported previously [5] in the presence of 200 U of low molecular weight heparin (LMWH). Exosomes and microvesicles (MVs) were isolated from the conditioned medium (48 h) as previously described [5]. For more details see supplementary information. Vesicles washed in cold PBS were lysed in SDS-loading buffer, subjected to ultracentrifugation, and supernatants processed for immunoblotting (or frozen at −80 °C). For

Results and discussion

In a previous study, we identified the presence of bovine antithrombin in the proteome of exosomes released by MDCK cells [5]. This was confirmed by western blotting. Under reducing conditions, a main band of ∼55 kDa was detected corresponding to “free” antithrombin [6] together with a less abundant larger band of ∼75 kDa compatible with the formation of a covalent complex between antithrombin and an unknown protein (Fig. 1A). Interestingly, the band of ∼75 kDa corresponding to complexed

Conclusion

We show in this article that antithrombin can be found incorporated into exosomes produced by antithrombin non-expressing cells. In the case of MDCK cells, bovine antithrombin from the fetal serum used in the culture medium was internalized by the cells in the presence of heparin, likely by endocytosis through interaction with an unknown membrane receptor, and later incorporated into exosomes where it appears to interact covalently with HTRA1.

Conflict of interest

The authors declare no competing financial interest.

Acknowledgements

Ginés Luengo-Gil holds a grant from the Spanish Society of Hematology and Hemotherapy (SEHH-FEHH), Irene Martínez-Martínez holds a Miguel Servet contract from the ISCIII. Miguel Quintanilla holds a grant (SAF2017-84183-R) from the Spanish Ministry of Science, Innovation and Universities and Irene Martínez-Martínez holds grants from ISCIII (CP13/00126 & FEDER and PI17/00050 & FEDER).

References (13)

There are more references available in the full text version of this article.
View full text